For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Portuguese researchers identified a type of immune cell that appears to travel to the pancreas to stimulate glucagon ...

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With the potential to significantly change consumer eating habits, they are ...

It uses a molecule that helps cells communicate called cyclic adenosine ... Mazdutide is both a GLP-1 agonist and a glucagon receptor agonist. It works in two ways to promote weight loss in ...

After adjustment for confounding variables, researchers found no increased suicide risk for GLP-1 receptor agonists versus DPP-4 inhibitors or SGLT-2 inhibitors.

To study how GLP-1 receptor agonists affect muscle and fat, the HKUMed research team used genetic data of more than 800,000 European participants from different genome-wide association studies (GWAS ...

"Our study brings GIPR in fat cells to light as a meaningful ... In recent years, several drugs targeting the glucagon-like peptide-1 receptor (GLP-1R) have received FDA approval for treating ...

Obese mice whose fat cells were genetically altered to ... multiple drugs that take aim at the glucagon-like peptide-1 receptor (GLP-1R) have been approved by the Food and Drug Administration ...